MURRAY HILL, N.J.--(BUSINESS WIRE)--C. R. Bard, Inc. (NYSE:BCR) today reported 2016 second quarter financial results. Second quarter 2016 net sales were $931.5 million, an increase of 8 percent over the prior-year period on an as-reported basis. Excluding the impact of foreign exchange, second quarter 2016 net sales increased 9 percent over the prior-year period.

For the second quarter 2016, net sales in the U.S. were $633.1 million, an increase of 7 percent over the prior-year period. Net sales outside the U.S. were $298.4 million, an increase of 11 percent from the prior-year period on an as-reported basis. Excluding the impact of foreign exchange, second quarter 2016 net sales outside the U.S. increased 14 percent over the prior-year period.

For the second quarter 2016, net income was $159.2 million and diluted earnings per share were $2.11. Adjusting for amortization of intangibles and certain items that affect the comparability of results between periods, as detailed in the tables below, second quarter 2016 net income was $192.2 million and diluted earnings per share were $2.54, an increase of 11 percent and 12 percent, respectively, as compared to second quarter 2015 results.

Timothy M. Ring, chairman and chief executive officer, commented, “We continue to see strong results as we prioritize product leadership across the globe. Our commitment to innovation and product differentiation, along with a focus on delivering economic benefits to the healthcare system, have driven global demand for our products, and our targeted investments in emerging markets continue to expand our presence internationally. We believe this investment approach positions us well to continue to provide attractive returns to our shareholders.”

In conjunction with the second quarter results, the company is also increasing 2016 financial guidance. For the full year 2016, net sales are forecasted to increase between 7 percent and 8 percent on an as-reported basis. Excluding the impact of foreign exchange, full year 2016 net sales are forecasted to increase between 8 percent and 9 percent over 2015. Full year 2016 diluted earnings per share, after adjusting for amortization of intangibles and certain items that affect comparability between periods are projected to be between $10.10 and $10.20, representing growth between 11 percent and 12 percent compared to full year 2015 results.

C. R. Bard, Inc. (www.crbard.com), headquartered in Murray Hill, NJ, is a leading multinational developer, manufacturer and marketer of innovative, life-enhancing medical technologies in the fields of vascular, urology, oncology and surgical specialty products.